Target intelligence / Profile preview

Neutrophil serine protease (NSP)

Target
NSP
Molecular classification
Enzyme, Serine protease, Hydrolase, Chymotrypsin family
01

Overview

Neutrophil serine proteases (NSPs) are a group of specialized enzymes, including neutrophil elastase, proteinase 3, cathepsin G, and NSP4, stored within the azurophilic granules of neutrophils. They play a fundamental role in the innate immune system by degrading engulfed pathogens within phagolysosomes and contributing to the formation of neutrophil extracellular traps (NETs). However, when released excessively into the extracellular space, NSPs can cause significant tissue damage by degrading structural proteins like elastin and collagen and by activating pro-inflammatory cytokines. This dysregulation is a primary driver of chronic inflammatory lung diseases such as bronchiectasis and chronic obstructive pulmonary disease (COPD). Therapeutic strategies targeting NSPs include direct inhibitors of individual enzymes or the inhibition of dipeptidyl peptidase 1 (DPP1), the master enzyme responsible for activating all NSPs during neutrophil development.

Other names
Neutrophil-derived serine proteasesPolymorphonuclear leukocyte serine proteasesNeutrophil elastase-like serine proteases
02

Mechanism of action

Inhibition of the enzymatic activity of mature proteases (e.g., elastase inhibitors) or inhibition of Dipeptidyl peptidase 1 (DPP1/Cathepsin C) to prevent the N-terminal activation of NSPs during neutrophil maturation in the bone marrow.

03

Biological functions

Immune responsePathogen degradationNeutrophil extracellular trap formationCytokine processingTissue remodelingDegranulation
04

Disease associations

InflammationChronic obstructive pulmonary disease (COPD)Cystic fibrosisBronchiectasisAcute respiratory distress syndrome (ARDS)Autoimmune diseaseAlpha-1 antitrypsin deficiency
05

Safety considerations

Increased risk of infection due to impaired pathogen killingPotential for impaired wound healingGingival inflammation (associated with Papillon-Lefèvre syndrome-like effects in DPP1 inhibition)Off-target protease inhibition
06

Interacting drugs

Brensocatib (INS1007)

5 more in the full profile.

07

Biomarkers

Neutrophil elastase activityProteinase 3 levelsCathepsin G activityDesmosine/Isodesmosine (elastin degradation markers)Blood neutrophil counts

Beyond the preview

Go deeper on Neutrophil serine protease (NSP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neutrophil serine protease (NSP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call